Please sign in to follow a disease.
Can a nose ointment and body wash prevent surgery wounds from getting worse?
NCT ID NCT06712433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if using a nose ointment and body wash before and during radiation, plus a special dye during surgery, can lower the chance of serious wound problems. About 31 people with soft tissue sarcoma in the leg will take part. The goal is to see if these low-cost steps help wounds heal better after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 31 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 2. Newly diagnosed soft tissue sarcoma arising from the lower extremity (defined as the tumor center arising at the level of the iliac crest or below) 3. Eligible for wide local excision 4. Eligible for external beam radiation therapy 5. Negative serum pregnancy test for women of childbearing potential \< 28 days prior to RT. 6. Informed consent signed and dated to participate in the study. 7. Willingness and ability to comply Exclusion Criteria: 1. Allergy to mupirocin and/or chlorhexidine 2. Active dermatologic condition in RT field 3. Tumor size \> 32cm 4. Prior RT overlapping with fields 5. Concurrent/prior invasive malignancy that could potentially interfere with proposed treatment. Individual cases can be discussed with PI prior to registration
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sarcoma,soft tissue are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UPMC Hillman Cancer Centers
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
- New drug combo shows promise for rare sarcoma
- New chemo combo shows promise for rare sarcoma
- New drug cocktail shows promise for rare sarcomas
- New study tracks how cancer surgery affects Kids' walking